Leadership & Pay ·
Vistagen Therapeutics appointed Douglas J. Williamson, M.D., as a director effective July 29, 2026
VTGNVistagen Therapeutics, Inc.
Vistagen Therapeutics appointed Douglas J. Williamson, M.D., as a director effective July 29, 2026. Dr. Williamson received stock options to purchase up to 40,826 shares at an exercise price of $0.2433 per share under the Company’s Director Compensation Plan. The options vest in equal annual installments over three years and have a ten-year term. Vistagen Therapeutics is a late clinical-stage biopharmaceutical company developing intranasal neuroscience product candidates.